Lu Hao Feng et al., IJSIT, 2016, 5(6),

Similar documents
Neuroendocrine Tumors

Management of Pancreatic Islet Cell Tumors

The watery diarrhea syndrome

DIABETES MELLITUS: COMPLICATION. Benyamin Makes Dept. of Anatomic Pathology FMUI - Jakarta

AN ARGUMENT FOR SURGERY FOR GASTRINOMA. Lauren Wilson R1 General Surgery

Unusual Pancreatic Neoplasms RTC 2/11/2011

Tumor markers. Chromogranin A. Analyte Information

Management of pancreatic neuroendocrine tumors in patients with MEN 1

Diagnosing and monitoring NET

Sandostatin LAR. Sandostatin LAR (octreotide acetate) Description

Index. Surg Oncol Clin N Am 15 (2006) Note: Page numbers of article titles are in boldface type.

Diagnosis abnormal morphology and /or abnormal biochemistry

Neuro-endocrine and pancreatic non-adenocarcinomas. Marc Engelbrecht, AMC, Amsterdam

A VIPER IN THE COURTYARD L A I L A ABUZA I D, M D

Type 2 gastric neuroendocrine tumor: report of one case

Systemic Therapy for Gastroenteropancreatic (GEP) Neuroendocrine Tumors and Lung Carcinoid

Gastrinoma: Medical Management. Haley Gallup

A case of persistent diarrhoea. Dr. Miles Levy, Dr. Jenny Prouten, Priya Jalota

Surgical treatment and prognosis of gastrinoma

Endocrinology and VHL: The adrenal and the pancreas

Diseases of the endocrine pancreas

Imaging and Management of Pancreatic Endocrine Tumors in MEN 1

What location in the gastrointestinal (GI) tract has tight, or impermeable, junctions between the epithelial cells?

Multiple endocrine neoplasia type 1: duodenopancreatic tumours

Table: CPT Codes / HCPCS Codes / ICD - 10 Codes ; Code Code Description; Information in the [brackets] below has been added for clarification

Gastrointestinal pathology 2018 lecture 4. Dr Heyam Awad FRCPath

Pancreatic polypeptide secreting tumors an institutional experience and review of the literature

Joy E.S. Ardill, PhD, MRCPath a, Thomas M. O Dorisio, MD b, *

Fig. 59 Malignant phaeochromocytoma, hepatic metastasis.

Gastroenteropancreatic Neuroendocrine Tumors in Multiple Endocrine Neoplasia Type 1

Surgical Management of Zollinger-Ellison Syndrome; State of the Art

A new bioassay of VIP: results in watery diarrhoea syndrome

UnitedHealthcare Pharmacy Clinical Pharmacy Programs

Zollinger-Ellison Syndrome

A retrospective analysis of neuroendocrine tumour of pancreas: a single institute study

Multiple endocrine neoplasia type 1 (MEN1) is an autosomal

Pharmacy Prior Authorization Somatostatin Analogs Clinical Guideline

Gastrointestinal Neuroendocrine Tumors: A Closer Look at the Characteristics of These Diverse Tumors

with malignant medullary thyroid carcinoma. 12 The therapy is focused on resection of the primary lesion. We describe a patient who was found to have

Endocrine Tumors of the Gastrointestinal System. F. V. Nowak Ohio University March 22, 2005

NEUROENDOCRINE CARCINOID TUMORS PANCREATIC NEUROENDOCRINE TUMORS

Pathology testing and Neuroendocrine tumours (NETs)

B. Environmental Factors. a. The major risk factor to papillary thyroid cancer is exposure to ionizing radiation, during the first 2 decades of life.

Chapter 20 The Digestive System Exam Study Questions

NET und NEC. Endoscopic and oncologic therapy

PEPTIDE HORMONES AS TUMOR MARKERS IN NEUROENDOCRINE GASTROINTESTINAL TUMORS

The pathology of pancreas

Neuroendocrine Tumours (NETs) - Treatment Pathway Toolkit. See inside for further information on rarer types of NETs

Small cell neuroendocrine carcinoma icd 10

Sunitinib Achieved Fast and Sustained Control of VIPoma. Symptoms

Endoscopic Ultrasound Is Highly Accurate and Directs Management in Patients With Neuroendocrine Tumors of the Pancreas

Rare GI Malignancies

ACTH-producing neuroendocrine tumor of the pancreas: a case report and literature review

PNET 3/7/2015. GI and Pancreatic NETs. The Postgraduate Course in Breast and Endocrine Surgery. Decision Tree. GI and Pancreatic NETs.

MINISYMPOSIUM MEN & VHL. N. W. THOMPSON From the Division of Endocrine Surgery, University of Michigan, Ann Arbor, MI, USA

Pancreatitis. Acute Pancreatitis

Unusual Neuroendocrine Tumors (NETs) AACE 27 th Annual Congress Meet-the-Expert Session May 17, Karel Pacak

Pancreatic Insulinoma Presenting. with Episodes of Hypoinsulinemic. Hypoglycemia in Elderly ---- A Case Report

Assistant Professor: Dr.Samer Al-Sawalhi (M.R.C.S.I)(M.D)

SOMATULINE DEPOT (lanreotide acetate)

Pancreas Quizzes c. Both A and B a. Directly into the blood stream (not using ducts)

Surgical treatment of neuroendocrine metastases

The Pancreas. Basic Anatomy. Endocrine pancreas. Exocrine pancreas. Pancreas vasculature. Islets of Langerhans. Acinar cells Ductal System

21/07/2017. CS Verbeke. Non-neoplastic disease of the pancreas PATHOLOGY OF NON-NEOPLASTIC PANCREATIC DISEASES

Pancreatic Lesions. Valerie Jefford Pediatric Surgery Rounds June 6, 2003

Multiple Endocrine Neoplasia Type 1

Disclosure of Relevant Financial Relationships

Case Scenario 1. Discharge Summary

Surgical Therapy of GEP-NET: An Overview

5/1/2010. Genetic testing in patients with endocrine tumors. Genetic testing in Patients with Endocrine Tumors

Surgical management of pancreatico-duodenal tumors in multiple endocrine neoplasia syndrome type 1

The Role of the Selective Arterial Secretagogue Injection Test for Non- Functional Pancreatic Neuroendocrine Tumor

Imaging of Neuroendocrine Metastases

An Unexpected Cause of Hypoglycemia

NeuroEndocrine Tumors Diagnostic and therapeutic challenges: introduction

EURO DIAGNOSTICA PRODUCT CATALOG RADIOIMMUNOASSAY (RIA)

Review. Pancreatic endocrine tumors: Recent advances

Imaging Pancreatic Neuroendocrine Tumors (PNETs): CT, MRI, EUS, Nuclear

Radiology Pathology Conference

PRINCESS MARGARET CANCER CENTRE CLINICAL PRACTICE GUIDELINES

Ligand-Directed AAVP to Deliver a Therapeutic Transgene to Neuroendocrine Tumors of the Pancreas

Retroperitonial Non Functional Neuroendocrine Tumor Of Pancreas Encircling Duodenum Without Obstruction

Endocrine pancreatic tumors: factors correlated with survival

Multiple endocrine neoplasia type 1 (MEN1) is an

A Case of Pancreatic Neuroendocrine Tumor presenting Iron Deficiency Anemia in a Patient with Neurofibromatosis Type 1

ADRENAL MEDULLARY DISORDERS: PHAEOCHROMOCYTOMAS AND MORE

PAPER. Lymph Nodes and Survival in Pancreatic Neuroendocrine Tumors

Enteroendocrine Tumors Other Than Carcinoid: A Review of Clinically Significant Advances

Diagnosis and Management of Multiple Endocrine Neoplasia Type 1 (MEN1)

Biopsy needle, thyroid gland, 74 technique, Bone hunger syndrome, 23

THE WHIPPLE PROCEDURE

Year 2004 Paper two: Questions supplied by Megan 1

Fast, automated, precise

PATHOLOGY MCQs. The Pancreas

Neuroendocrine Tumors: Just the Basics. George Fisher, MD PhD

SIMULTANEOUSLY PRESENTATION OF TWO PARANEOPLASTIC SYNDROMES IN A PATIENT WITH LUNG CARCINOMA

CASE 1 11/1/2016 HEPATOBILIARY IMAGING CASE PRESENTATIONS DECLARATION. Dr. Chirag Patel ORGAN IMAGING yr old lady

Pancreatic Cancer Early Detection, Diagnosis, and Staging

SUPPLEMENTARY INFORMATION

Pancreatic Neuroendocrine Tumor with Atypical Radiologic Presentation

Transcription:

AN UNUSUAL PRESENTATION OF PANCREATIC VASOACTIVE INTESTINAL PEPTIDE TUMOUR (VIP OMAS) WITH GASTROINTESTINAL STROMAL TUMOUR (GIST) WITHOUT HYPOKALEMIA AND HPERCALCEMIA: A CASE REPORT WITH REVIEW ARTICLES Shamsad Ahmad 1, Li Mi 2 and Lu Hao Feng 3* 1Department of Surgery, Clinical Medical College of Yangtze University, Jingzhou, Hubei 434000, China 2Department of Hepatobiliary Surgery, the First Affiliated Hospital of Yangtze University, Jingzhou, Hubei 434000, China 3*Dr. Lu Hao Feng, Department of Hepatobiliary Surgery, Clinical Medical College of Yangtze University, No.55, Jianghan Road, ShaShi District, Jingzhou, Hubei,434000, China. ABSTRACT Pancreatic VIPoma are rare neuroendocrine tumour of gastrointestinal tract. These tumours secret excessive amount of vasoactive intestinal peptides, which simultaneously leads to chronic diarrhea wth electrolytes disturbances. The annual incidence of tumour is one in 10000000 individual in general population. Most commonly presented with diarrhea associated with electrolyte disturbances. Here we are presenting a case of 65 years female patient, complaining diarrhea for more than three months and surprisingly laboratory reports shows there is normal serum potassium and calcium level. Thus this is unusual presentation which is significant for both literature and scientific purpose. Key words: Pancreatic VIPoma, Hypokalemia, Gastric GIST, GIP-NET (Gastrointestinal-pancreatic neuroendocrine tumours) 528

INTRODUCTION In 1958 Verner and Morrison [1] describes two cases of severe watery diarrhea non-associated with insulin secreting islet cell adenoma of pancreas. This association was previously known as VERNER MORRISON SYNDROME or also known as WHDA (Watery, Diarrhea, Hypokalemia, Achlorhydria) or cholera of pancreas. Other features are cutaneous flushing, hypokalemia associated renal failure, reduced or absent gastric secretion, Diabetes Mellitus and Hypercalcemia[2,3]. An association between ganglioneuroblastoma and diarrhea are usually seen in children[4]. Vasoactive intestinal peptide is a basic 28 amino acid peptide present in central and peripheral nervous system. Its role is as a putative neurotransmitter, which is supported by neurophysiological experiments [5]. In 1973 raised plasma and tumour concentration of VIP was demonstrated in patient with ganglioneuroblastoma and secretory diarrhea [6]. We present single case of pancreatic VIPoma without hypokalemia and hypercalcemia. CASE REPORT A 65 years old female patient, farmer by occupation, presented with three months history of watery diarrhea varying three to four episodes per day. The diarrhea was not-associated with pain, no abdominal distension, no blood in stool. In this period patient was afebrile. The diarrhea is also not-associated with nausea or vomiting. Upper gastrointestinal endoscopy shows 2cm 2 small nodular mass in body of stomach and CT scan shows Probable GIST. Later ultrasonography andct scan shows small cystic lesion in tail of pancreas. Her investigation are as follow: Vitals Blood pressure 130/75 mmhg Temperature 36.50c Pulse 78/min Respiratory Rates 20/ min Biochemical findings K + 3.5 mmol/l Na + 142.3 mmol/l Cl - 108.0 mmol/l Lipase 264U/l Albumen 271.20 mg/l Amylase 187U/l Ca ++ 2mom/l 529

Figure 1 Figure 2 Figure 3 530

Figure 4 DISCUSSION The neuroendocrine tumour of pancreatic islet cells can be functional tumour often shows malignant courses (Table -1) [7-9] Tumor (Penetrance %) Sites Malignancy (%) Non-functioning (60 100) Insulinoma (21) Gastrinoma (50) Glucagonoma (3) Somatostatinoma (1) VIP-oma (1) GHRH-oma (1) Pancres, duodenum (>80%), duodenum/ jejunum (44%), duodenum (10%) 64-92 12-20 60 35 70 40 30 Table 1 VIPoma syndromes also known as VERNER-MORRISON SYNDROME is usually present with WDHA syndrome [10]. Pancreatic tumour are not sole origin of VIP secretion [11,12]. It may also produced by neuroblastoma, bronchogenic carcinoma, ganglioneuroblastoma or pheochromocytoma [13, 14]. As VIPoma present with watery diarrhea with hypokalemia our case is atypical with clinical features of VIPoma. In our case these is not-association of hypokalemia or hypercalcemia or achlorhydria. These features make difficult for the initial diagnosis of disease. Other features of pancreatic VIPomas are consistent with our caase, as study shows peak incidence in 4 th or 5 th decade [15,16] 531

The case is also associated with GIST which makes it rarest [8-10]. The VIPoma in our case is present in tail of pancreas (figure 1-figure 4) as the typical presentation where 75% of tumour presents in tail or body of pancreas [17]. Surgical resection and pathological study confirms our diagnosis. CONCLUSION Pancreatic vipoma with gastric GIST are neuroendocrine tumours with not nerely present with WDHA syndromes. It can also present without hypokalemia or hypercalcemia. REFERENCES 1. Verner JV, Morrison AB. Islet cell tumour and a syndrome of refractorywatery diarrhoea and hypokalaemia. Am J Med 1958;25:374-80. 2. 2.Kraft AR, Tompkins RK, Zollinger R. Recognition and management ofthe diarrhoea syndrome caused by nonbeta islet cell tumours of thepancreas. AmJ7 Surg 1970;119:163-70. 3. Verner JV, Morrison AB. Endocrine pancreatic islet disease with Diarrhoea. Report of a case due to diffuse hyperplasia of nonbeta islettissue with a review of 54 additional cases. Arch Intern Med 1974;133:492-500. 4. Green M, Cooke RE, Lattanzi W. Occurrence of chronic diarrhoea inthree patients with ganglioneuromas. Pediatrics 1959;23:951-5. 5. Fahrenkrug J, Haglund U, Jodal M, Lundgren 0, Olbe L, Schaffalitskyde Muckadell OB. Nervous release of vasoactive intestinal polypeptidein the gastrointestinal tract of cats: possible physiological implications.j7 Physiol 1978;284:291-305. 6. Said SI, Mutt V. Polypeptide with broad biological activity: isolation fromsmall intestine. Science 1970 ;169 :1217-8. 7. Marx, S.; Spiegel, A.M.; Skarulis, M.C.; Doppman, J.L.; Collins, F.S.; Liotta, L.A. Multiple endocrine neoplasia type 1: Clinical and genetic topics. Ann. Intern. Med. 1998, 129, 484 494. 8. Calender, A.; Cadiot, G.; Mignon M. Multiple endocrine neoplasia type 1: Genetic and clinical aspects. Gastroenterol. Clin. Biol. 2001, 25, 38 48. 9. Chanson, P.; Cadiot, G.; Murat, A. Management of patients and subjects at risk for multiple endocrine neoplasia type 1: MEN 1. GENEM 1. Groupe d Etude des Néoplasies Endocriniennes Multiples de type 1. Horm. Res. 1997, 47, 211 220. 532

10. Kaltsas, G.A.; Besser, G.M.; Grossman, A.B. The diagnosis and medical management of advanced neuroendocrine tumors. Endocr. Rev. 2004, 25, 458 511. 11. 11.O Dorisio TM, Mekhjian HS, Gaginella TS: Medical therapy of VIPomas. [review] Endocrinol MetabClin North Am 1989; 18: 545 556. 12. Fraker DL, Norton JA: The role of surgery in the management of islet cell tumors. [review] GastroenterolClin North Am 1989; 18: 805 830. 13. Sheppard BC, Norton JA, Doppman JL et al: Management of islet cell tumors in patients with multiple endocrine neoplasia: a prospective study. Surgery 1989; 106: 1108 1118. 14. Ronnov-Jensen D, Gether U, Fahrenkrug J: PreproVIP-derived peptides in tissue and plasma from patients with VIP-producing tumors. [review] Eur J Clin Invest 1991; 21: 154 160. 15. Bartsch, D.K.; Fendrich, V.; Langer, P.; Celik, I.; Kann, P.H.; Rothmund, M. Outcome of duodenopancreatic resections in patients with multiple endocrine neoplasia type 1. Ann. Surg. 2005, 242, 757 766. 16. Oberg, K.; Astrup, L.; Eriksson, B.; Falkmer, S.E.; Falkmer, U.G.; Gustafsen, J.; Haglund, C.; Knigge, U.; Vatn, M.H.; Välimäki, M.; et al. Guidelines for the management of gastroenteropancreatic neuroendocrine tumours (including bronchopulmonary and thymic neoplasms). Part I and II-general overview. Acta Oncol. 2004, 43, 617 625. 17. Delcore R and Friesen SR: Gastrointestinal neuroendocrine tumors. J Am Coll Surg 178: 187-211, 1994. 533